Robertson, Lexeo Therapeutics CLO, sells $31,529 in LXEO stock

Published 18/10/2025, 00:36
Robertson, Lexeo Therapeutics CLO, sells $31,529 in LXEO stock

Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics Inc (NASDAQ:LXEO), sold a total of 3,526 shares of common stock on October 17, 2025. The sales, executed in multiple transactions, generated $31,529. The transaction comes as the stock shows strong momentum, with InvestingPro data revealing a remarkable 253% return over the past six months and a current market capitalization of $473 million.

The price per share for the sales ranged from $8.53 to $9.59. Specifically, 3,486 shares were sold at a weighted average price of $8.935, and 40 shares were sold at a weighted average price of $9.561.

On October 15, Robertson also acquired 9,900 shares of Lexeo Therapeutics , Inc. common stock. These shares were acquired through a non-taxable transaction.

Following these transactions, Robertson directly owns 68,930 shares of Lexeo Therapeutics.

In other recent news, Lexeo Therapeutics announced a public offering and concurrent private placement, aiming for gross proceeds of approximately $135 million. The company has priced its public offering at $8.00 per share, offering 15,625,000 shares, with an option for underwriters to purchase an additional 2,343,750 shares. This development follows Lexeo’s announcement of additional LX2020 PKP2 data. In response to the public offering, Stifel has adjusted its price target for Lexeo Therapeutics from $20.00 to $18.00, though it maintains a Buy rating on the stock. Meanwhile, H.C. Wainwright has increased its price target to $15.00 from $9.00, citing positive feedback from the FDA regarding the company’s therapy. The FDA’s feedback included openness to a pooled Phase 1/2 and pivotal dataset and acceptance of an earlier LVMI assessment for accelerated approval. These recent developments are part of Lexeo’s ongoing efforts to advance its clinical-stage genetic medicine initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.